Originally developed as Victoza for type 2 diabetes, liraglutide at higher doses (as Saxenda) has been clinically proven for chronic weight management in non-diabetic patients as well
Canada added the cardiovascular label in 2024, and provincial formularies followed by mid-2025, expanding patient eligibility
Esas cifras proceden de estudios con poblaciones, duraciones, criterios de inclusin y variables de anlisis diferentes, y no son comparables entre s
Two days later, it binned the whole plan
You can trust us on this one
Halminen J, Sattaer N, Rawshani A et al (2022) Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes